NHS to offer second MenB vaccine after deadly Kent outbreak
Vaccines were offered to thousands of people who may have been exposed, including university students and school pupils in the area.
www.bbc.comHere’s a concise update on the latest news about MenB vaccines.
Key points
- There is ongoing activity in the UK around targeted MenB vaccination efforts in response to outbreaks, including plans and clinics expanding access in Kent and surrounding areas. This includes second-dose recommendations and expansion to affected groups.[1][3][5]
- Public health authorities have emphasized the vaccine’s role in protecting against most circulating MenB strains and noted cross-protection against certain other meningococcal strains, with additional context about related recommendations and policy discussions in 2024–2026.[4][8]
- Media coverage in early 2026 highlighted high demand at Kent-area vaccination sites, with queues and rapid uptake among students and local residents, and ongoing efforts to manage appointments and eligibility criteria.[3][9]
- Some outlets discuss broader questions about MenB vaccination policies for older teens and young adults, and whether teenagers should be routinely offered MenB vaccination in the context of outbreaks.[6][10]
Representative sources
- NHS and UK government updates on Kent outbreak response, clinic rollouts, and dosing schedules.[8][3]
- Public-facing explanations of MenB vaccine coverage and cross-protection against related diseases.[1][4]
- News coverage of vaccination-site demand and patient access during the Kent outbreak.[9]
If you want, I can pull the most recent local updates for Los Angeles/California or summarize guidance from US public health authorities on MenB vaccination, including who is recommended to receive it and any recent changes. Also, I can provide a brief explainer comparing MenB vaccine efficacy, timing, and common side effects. Please tell me which region or aspect you’d like prioritized.
Citations
- MenB vaccination in Kent and targeted programs; dosing and eligibility.[3][1]
- Cross-protection and policy discussions around MenB vaccines.[4][1]
- Media reports on clinic access and demand in Kent.[9]